Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carboplatin + nab-paclitaxel + nivolumab
- Development stage
- Phase 2
- Lead developer
- Bristol Myers Squibb
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
This is a combination regimen consisting of three agents: - **Carboplatin** is a platinum-based chemotherapy that induces DNA crosslinking, leading to apoptosis in rapidly dividing cells. - **Nab-paclitaxel** (nanoparticle albumin-bound paclitaxel) is a microtubule inhibitor formulated with albumin nanoparticles to enhance delivery and reduce hypersensitivity reactions compared to conventional paclitaxel. It disrupts microtubule function, inhibiting cell division. - **Nivolumab** is a monoclonal antibody immune checkpoint inhibitor targeting the programmed death-1 (PD-1) receptor on T cells. By blocking PD-1, it enhances anti-tumor immune responses. This combination has been investigated primarily for advanced non-small cell lung cancer (NSCLC), including both squamous and non-squamous histologies, as well as for locoregionally advanced HPV-positive oropharyngeal cancer. The regimen leverages the cytotoxic effects of chemotherapy with the immunomodulatory action of nivolumab to improve tumor response rates and survival outcomes[1][5][8].
- Other names
- carboplatin plus nab-paclitaxel and nivolumabnivo + nab-paclitaxel/carboplatin
02
Targets
DNAPDCD1 (Programmed cell death protein 1 receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on carboplatin + nab-paclitaxel + nivolumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carboplatin + nab-paclitaxel + nivolumab.